KTOV NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Kitov Pharmaceutical Holdings Ltd. To Contact The Firm

NEW YORK, Feb. 7, 2017

The investigation focuses on whether the Company and its executives violated federal securities laws by failing to disclose that some of its executives might have been involved in publishing false information.

Specifically, on February 6, 2017, the Israeli publication Calcalist reported that Kitov's chief executive officer, Isaac Israel, had been detained and questioned by the Israeli Securities Authority.  Citing court documents, the publication also stated that the Company might have published misleading information regarding findings from an independent committee appointed to check clinical trial results of one of the Company's drugs.

Request more information now by clicking here:  www.faruqilaw.com/KTOV. There is no cost or obligation to you.

Take Action

If you invested in Kitov stock or options and would like to discuss your legal rights, visit www.faruqilaw.com/KTOV.  You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding Kitov's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising.  The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).  Prior results do not guarantee or predict a similar outcome with respect to any future matter.  We welcome the opportunity to discuss your particular case.  All communications will be treated in a confidential manner.